Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial
Authors
Keywords
-
Journal
Trials
Volume 22, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-10
DOI
10.1186/s13063-021-05132-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China
- (2020) Zunyou Wu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer
- (2020) Sufang Tian et al. Journal of Thoracic Oncology
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Is COVID-19 receiving ADE from other coronaviruses?
- (2020) Jason A. Tetro MICROBES AND INFECTION
- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- (2020) Na Zhu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2
- (2020) Renhong Yan et al. SCIENCE
- Pathological findings of COVID-19 associated with acute respiratory distress syndrome
- (2020) Zhe Xu et al. Lancet Respiratory Medicine
- Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
- (2020) Chuan Qin et al. CLINICAL INFECTIOUS DISEASES
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
- (2020) Chenguang Shen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- (2020) Fei Zhou et al. LANCET
- Effectiveness of convalescent plasma therapy in severe COVID-19 patients
- (2020) Kai Duan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
- (2020) Ling Li et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Early safety indicators of COVID-19 convalescent plasma in 5000 patients
- (2020) Michael J. Joyner et al. JOURNAL OF CLINICAL INVESTIGATION
- The National Early Warning Score 2 (NEWS2)
- (2019) Gary B Smith et al. CLINICAL MEDICINE
- Epidemiology and Immune Pathogenesis of Viral Sepsis
- (2018) Gu-Lung Lin et al. Frontiers in Immunology
- Anti-Gal and Anti-Neu5Gc Responses in Nonimmunosuppressed Patients After Treatment With Rabbit Antithymocyte Polyclonal IgGs
- (2017) Apolline Salama et al. TRANSPLANTATION
- Parainfluenza virus 5 upregulates CD55 expression to produce virions with enhanced resistance to complement-mediated neutralization
- (2016) Yujia Li et al. VIROLOGY
- A hazard ratio was estimated by a ratio of median survival times, but with considerable uncertainty
- (2014) Jordi Cortés et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of 10-Day Monotherapy With BMS-986001, a Novel HIV NRTI, in Treatment-Experienced HIV-1–Infected Subjects
- (2013) Laurent Cotte et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started